Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
IP Group shares climb 9% on potential royalties from Pfizer's $7.3bn Metsera deal
05:35am, Monday, 13'th Oct 2025
Shares in IP Group PLC (LSE:IPO) rose 9% on Monday after investors welcomed the potential for future royalty income from Metsera, a biotech company that Pfizer has agreed to acquire for up to $7.3 bil
IP Group in line for future royalties from Pfizer's drug deal
02:43am, Monday, 13'th Oct 2025
IP Group PLC (LSE:IPO) could see future royalty income from a new wave of obesity drugs being developed by Metsera, a biotech company that Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed to buy for up to $
4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer
02:28pm, Sunday, 12'th Oct 2025
Sometimes, things are going great for a stock with potentially more good news on the way. In other cases, things are going so badly for a stock that it almost has nowhere to go but up.
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
10:15am, Friday, 10'th Oct 2025
Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower drug prices
Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
09:00am, Friday, 10'th Oct 2025
Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior mark
2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now
06:45am, Friday, 10'th Oct 2025
There are several compelling reasons to invest in pharmaceutical companies, especially when the economy isn't doing well. Since they belong to a defensive industry, drugmakers tend to perform better t
Here's How This Pharmaceutical Giant Is Protecting Itself From President Trump's Tariffs. Should It Matter to Investors?
03:18am, Friday, 10'th Oct 2025
As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, Pfizer (PF
Here's Why Pfizer (PFE) Fell More Than Broader Market
06:46pm, Thursday, 09'th Oct 2025
In the latest trading session, Pfizer (PFE) closed at $25.24, marking a -1.71% move from the previous day.
Pfizer Declares Fourth-Quarter 2025 Dividend
04:30pm, Thursday, 09'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to
Wilsey Discloses $2.9 Million Purchase of Pfizer Stock Amid Landmark Trump Deal
11:35am, Thursday, 09'th Oct 2025
Wilsey Asset Management disclosed the purchase of Pfizer shares valued at an estimated $2.9 million during the third quarter, according to an SEC filing released Wednesday.
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead
10:15am, Wednesday, 08'th Oct 2025
On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
09:50am, Wednesday, 08'th Oct 2025
Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
09:46am, Wednesday, 08'th Oct 2025
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman
07:00am, Wednesday, 08'th Oct 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $PFE #ADCs--Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman.
Life sciences sentiment rises as Pfizer deal eases tariff concerns
12:32pm, Tuesday, 07'th Oct 2025
Sentiment towards life sciences tools and diagnostics firms in North America is turning positive after an agreement between the Trump Administration and Pfizer Inc (NYSE:PFE, ETR:PFE) has significantl
